Ceritinib-d7

• UNSPSC Description:

  Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

• Target Antigen:

  Anaplastic lymphoma kinase (ALK); IGF-1R; Insulin Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others;Protein Tyrosine Kinase/RTK

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Endocrinology

• Purity:

  98.00

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(C2CCNCC2)C=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3)=C1

• Molecular Weight:

  565.18

• References & Citations:

  [1]Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1632484-77-5